お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
デフォルト表紙
市場調査レポート
商品コード
1002729

結核薬市場調査レポート:疾患タイプ別(活動性結核、潜伏性結核)、薬剤クラス別(併用薬、一次抗結核薬、二次抗結核薬)-2026年までの予測-COVID-19の累積的影響

Tuberculosis Drugs Market Research Report by Disease Type, by Drug Class, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19

出版日: | 発行: 360iResearch LLP | ページ情報: 英文 185 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=112.06円
結核薬市場調査レポート:疾患タイプ別(活動性結核、潜伏性結核)、薬剤クラス別(併用薬、一次抗結核薬、二次抗結核薬)-2026年までの予測-COVID-19の累積的影響
出版日: 2021年06月01日
発行: 360iResearch LLP
ページ情報: 英文 185 Pages
納期: 即日から翌営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の結核薬の市場規模は、2020年の16億2,215万米ドルから2025年末までに20億9,509万米ドルに拡大すると予測されています。

COVID-19は、未曾有の世界的な公衆衛生上の緊急事態であり、あらゆる業界に影響を及ぼしてきました。この長期的影響は、予測期間中に業界の成長に影響を与えると予測されています。私たちが進めている調査では、根底にあるCOVID-19の問題と今後の道筋を確実に扱うために、調査範囲を広げています。当レポートは、消費者の行動と需要の変化、購入パターン、サプライチェーンの再ルーティング、現在の市場動向、および政府の重要な介入などを考慮しながら、COVID-19について洞察を提供しています。アップデートされた調査では、COVID-19が市場に及ぼす影響を考慮し、洞察、分析、予測などを提供しています。

当レポートでは、結核薬市場について調査し、市場の概要とともに、疾患タイプ別、薬剤クラス別、地域別の動向、COVID-19の累積的影響、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 序文

  • 調査の目的
  • 市場セグメンテーションと範囲
  • 調査対象年
  • 通貨と価格
  • 言語
  • 制限事項
  • 利害関係者

第2章 調査手法

  • 調査プロセス
    • 定義:調査目的
    • 決定:調査デザイン
    • 準備:調査機器
    • 収集:データソース
    • 分析:データの解釈
    • 策定:データ検証
    • 公開:調査レポート
    • 繰り返し:レポートの更新
  • 調査の実行
    • 開始:調査プロセス
    • 計画:調査計画作成
    • 実行:調査実施
    • 検証:発見と分析
    • 出版物:調査報告
  • 調査成果

第3章 エグゼクティブサマリー

  • イントロダクション
  • 市場の見通し
  • 薬剤クラス別見通し
  • 疾患タイプ別見通し
  • 最終用途産業別見通し
  • 地域別見通し
  • 競合他社別見通し

第4章 市場概要

  • イントロダクション
  • COVID-19の累積的影響

第5章 市場の洞察

  • 市場力学
    • 促進要因
    • 抑制要因
    • 市場機会
    • 課題
  • ポーターズファイブフォース分析
    • 新規参入業者の脅威
    • 代替品の脅威
    • 顧客の交渉力
    • 供給企業の交渉力
    • 業界の競争

第6章 世界の結核薬市場、疾患タイプ別

  • 活動性結核
  • 潜伏性結核

第7章 世界の結核薬市場、薬剤クラス別

  • 併用薬
  • 一次抗結核薬
    • エタンブトール
    • イソニアジド
    • ピラジナミド
    • リファンピン
  • 二次抗結核薬
    • カプレオマイシン
    • エチオナミド
    • レボフロキサシン
    • ストレプトマイシン

第8章 南北アメリカの結核薬市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第9章 アジア太平洋地域の結核薬市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • 韓国
  • タイ

第10章 欧州、中東・アフリカの結核薬市場

  • フランス
  • ドイツ
  • イタリア
  • オランダ
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • アラブ首長国連邦
  • 英国

第11章 競合情勢

  • FPNVポジショニングマトリックス
    • 象限
    • 事業戦略
    • 製品の満足度
  • 市場ランキング分析
  • 市場シェア分析
  • 競合他社のSWOT分析
  • 競合シナリオ
    • 合併と買収
    • 契約、コラボレーション、およびパートナーシップ
    • 新製品の発売と強化
    • 投資と資金調達
    • 賞、表彰、拡大

第12章 企業のユーザビリティプロファイル

  • AstraZeneca
  • Bayer AG
  • Cipla Ltd.
  • Lupin
  • Merck & Co.
  • Novartis AG
  • Otsuka Novel Products
  • Pfizer
  • Sandoz International Gmbh
  • Sanofi

第13章 付録

  • ディスカッションガイド
  • ライセンスと価格
図表

LIST OF FIGURES

  • FIGURE 1. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, 2020 VS 2026 (USD MILLION)
  • FIGURE 2. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2020 (USD MILLION)
  • FIGURE 3. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2020 (USD MILLION)
  • FIGURE 4. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 (USD MILLION)
  • FIGURE 5. GLOBAL TUBERCULOSIS DRUGS MARKET: MARKET DYNAMICS
  • FIGURE 6. GLOBAL TUBERCULOSIS DRUGS MARKET: PORTERS FIVE FORCES ANALYSIS
  • FIGURE 7. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2020 VS 2026 (%)
  • FIGURE 8. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2020 VS 2026 (USD MILLION)
  • FIGURE 9. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2026
  • FIGURE 10. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY ACTIVE TB, 2018-2026 (USD MILLION)
  • FIGURE 11. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY ACTIVE TB, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 12. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY LATENT TB, 2018-2026 (USD MILLION)
  • FIGURE 13. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY LATENT TB, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 14. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2020 VS 2026 (%)
  • FIGURE 15. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2020 VS 2026 (USD MILLION)
  • FIGURE 16. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2026
  • FIGURE 17. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY COMBINATION DRUGS, 2018-2026 (USD MILLION)
  • FIGURE 18. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY COMBINATION DRUGS, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 19. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2026 (USD MILLION)
  • FIGURE 20. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 21. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY ETHAMBUTOL, 2018-2026 (USD MILLION)
  • FIGURE 22. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY ETHAMBUTOL, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 23. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY ISONIAZID, 2018-2026 (USD MILLION)
  • FIGURE 24. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY ISONIAZID, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 25. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY PYRAZINAMIDE, 2018-2026 (USD MILLION)
  • FIGURE 26. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY PYRAZINAMIDE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 27. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY RIFAMPIN, 2018-2026 (USD MILLION)
  • FIGURE 28. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY RIFAMPIN, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 29. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2026 (USD MILLION)
  • FIGURE 30. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 31. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY CAPREOMYCIN, 2018-2026 (USD MILLION)
  • FIGURE 32. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY CAPREOMYCIN, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 33. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY ETHIONAMIDE, 2018-2026 (USD MILLION)
  • FIGURE 34. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY ETHIONAMIDE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 35. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY LEVOFLOXACIN, 2018-2026 (USD MILLION)
  • FIGURE 36. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY LEVOFLOXACIN, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 37. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY STREPTOMYCIN, 2018-2026 (USD MILLION)
  • FIGURE 38. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY STREPTOMYCIN, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 39. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
  • FIGURE 40. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 41. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY GEOGRAPHY, 2026
  • FIGURE 42. ARGENTINA TUBERCULOSIS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 43. BRAZIL TUBERCULOSIS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 44. CANADA TUBERCULOSIS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 45. MEXICO TUBERCULOSIS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 46. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 47. CALIFORNIA TUBERCULOSIS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 48. FLORIDA TUBERCULOSIS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 49. ILLINOIS TUBERCULOSIS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 50. NEW YORK TUBERCULOSIS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 51. OHIO TUBERCULOSIS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 52. PENNSYLVANIA TUBERCULOSIS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 53. TEXAS TUBERCULOSIS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 54. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
  • FIGURE 55. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 56. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY GEOGRAPHY, 2026
  • FIGURE 57. CHINA TUBERCULOSIS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 58. INDIA TUBERCULOSIS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 59. INDONESIA TUBERCULOSIS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 60. JAPAN TUBERCULOSIS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 61. MALAYSIA TUBERCULOSIS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 62. PHILIPPINES TUBERCULOSIS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 63. SOUTH KOREA TUBERCULOSIS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 64. THAILAND TUBERCULOSIS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 65. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
  • FIGURE 66. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
  • FIGURE 67. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY GEOGRAPHY, 2026
  • FIGURE 68. FRANCE TUBERCULOSIS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 69. GERMANY TUBERCULOSIS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 70. ITALY TUBERCULOSIS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 71. NETHERLANDS TUBERCULOSIS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 72. QATAR TUBERCULOSIS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 73. RUSSIA TUBERCULOSIS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 74. SAUDI ARABIA TUBERCULOSIS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 75. SOUTH AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 76. SPAIN TUBERCULOSIS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 77. UNITED ARAB EMIRATES TUBERCULOSIS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 78. UNITED KINGDOM TUBERCULOSIS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
  • FIGURE 79. GLOBAL TUBERCULOSIS DRUGS MARKET: FPNV POSITIONING MATRIX
  • FIGURE 80. GLOBAL TUBERCULOSIS DRUGS MARKET: SHARE, BY QUADRANT, 2020
  • FIGURE 81. GLOBAL TUBERCULOSIS DRUGS MARKET: SHARE, BY COMPANY, 2020
  • FIGURE 82. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL TUBERCULOSIS DRUGS MARKET, BY TYPE

LIST OF TABLES

  • TABLE 1. GLOBAL TUBERCULOSIS DRUGS MARKET: MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016-2020
  • TABLE 3. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 4. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY ACTIVE TB, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 5. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY LATENT TB, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 6. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 7. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY COMBINATION DRUGS, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 8. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 9. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY ETHAMBUTOL, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 10. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY ISONIAZID, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 11. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY PYRAZINAMIDE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 12. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY RIFAMPIN, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 13. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 14. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY CAPREOMYCIN, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 15. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY ETHIONAMIDE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 16. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY LEVOFLOXACIN, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 17. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY STREPTOMYCIN, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 18. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 19. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 20. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 21. ARGENTINA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 22. ARGENTINA TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 23. BRAZIL TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 24. BRAZIL TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 25. CANADA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 26. CANADA TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 27. MEXICO TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 28. MEXICO TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 29. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 30. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 31. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 32. CALIFORNIA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 33. CALIFORNIA TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 34. FLORIDA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 35. FLORIDA TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 36. ILLINOIS TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 37. ILLINOIS TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 38. NEW YORK TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 39. NEW YORK TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 40. OHIO TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 41. OHIO TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 42. PENNSYLVANIA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 43. PENNSYLVANIA TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 44. TEXAS TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 45. TEXAS TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 46. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 47. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 48. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 49. CHINA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 50. CHINA TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 51. INDIA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 52. INDIA TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 53. INDONESIA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 54. INDONESIA TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 55. JAPAN TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 56. JAPAN TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 57. MALAYSIA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 58. MALAYSIA TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 59. PHILIPPINES TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 60. PHILIPPINES TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 61. SOUTH KOREA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 62. SOUTH KOREA TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 63. THAILAND TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 64. THAILAND TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 65. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 66. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 67. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 68. FRANCE TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 69. FRANCE TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 70. GERMANY TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 71. GERMANY TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 72. ITALY TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 73. ITALY TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 74. NETHERLANDS TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 75. NETHERLANDS TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 76. QATAR TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 77. QATAR TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 78. RUSSIA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 79. RUSSIA TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 80. SAUDI ARABIA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 81. SAUDI ARABIA TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 82. SOUTH AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 83. SOUTH AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 84. SPAIN TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 85. SPAIN TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 86. UNITED ARAB EMIRATES TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 87. UNITED ARAB EMIRATES TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 88. UNITED KINGDOM TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 89. UNITED KINGDOM TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2026 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 90. GLOBAL TUBERCULOSIS DRUGS MARKET: SCORES
  • TABLE 91. GLOBAL TUBERCULOSIS DRUGS MARKET: BUSINESS STRATEGY
  • TABLE 92. GLOBAL TUBERCULOSIS DRUGS MARKET: PRODUCT SATISFACTION
  • TABLE 93. GLOBAL TUBERCULOSIS DRUGS MARKET: RANKING
  • TABLE 94. GLOBAL TUBERCULOSIS DRUGS MARKET: SHARE, BY QUADRANT, 2020
  • TABLE 95. GLOBAL TUBERCULOSIS DRUGS MARKET: SHARE, BY COMPANY, 2020
  • TABLE 96. GLOBAL TUBERCULOSIS DRUGS MARKET: MERGER & ACQUISITION
  • TABLE 97. GLOBAL TUBERCULOSIS DRUGS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
  • TABLE 98. GLOBAL TUBERCULOSIS DRUGS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
  • TABLE 99. GLOBAL TUBERCULOSIS DRUGS MARKET: INVESTMENT & FUNDING
  • TABLE 100. GLOBAL TUBERCULOSIS DRUGS MARKET: AWARD, RECOGNITION, & EXPANSION
  • TABLE 101. GLOBAL TUBERCULOSIS DRUGS MARKET: LICENSE & PRICING
  • TABLE 102. GLOBAL TUBERCULOSIS DRUGS MARKET: CONTACT DETAILS
目次
Product Code: MRR-03252A5F9278

The Global Tuberculosis Drugs Market size was estimated at USD 1,622.15 Million in 2020 and expected to reach USD 1,715.42 Million in 2021, at a Compound Annual Growth Rate (CAGR) 6.08% to reach USD 2,312.60 Million by 2026.

Market Statistics:

The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.

Market Segmentation & Coverage:

This research report categorizes the Tuberculosis Drugs to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Disease Type, the Tuberculosis Drugs Market was studied across Active TB and Latent TB.

Based on Drug Class, the Tuberculosis Drugs Market was studied across Combination Drugs, First-line Anti-TB Drugs, and Second-line Anti-TB Drugs. The First-line Anti-TB Drugs is further studied across Ethambutol, Isoniazid, Pyrazinamide, and Rifampin. The Second-line Anti-TB Drugs is further studied across Capreomycin, Ethionamide, Levofloxacin, and Streptomycin.

Based on Geography, the Tuberculosis Drugs Market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific is further studied across China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Tuberculosis Drugs Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Tuberculosis Drugs Market, including AstraZeneca, Bayer AG, Cipla Ltd., Lupin, Merck & Co., Novartis AG, Otsuka Novel Products, Pfizer, Sandoz International Gmbh, and Sanofi.

The report provides insights on the following pointers:

  • 1. Market Penetration: Provides comprehensive information on the market offered by the key players
  • 2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
  • 3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
  • 4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
  • 5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

  • 1. What is the market size and forecast of the Global Tuberculosis Drugs Market?
  • 2. What are the inhibiting factors and impact of COVID-19 shaping the Global Tuberculosis Drugs Market during the forecast period?
  • 3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Tuberculosis Drugs Market?
  • 4. What is the competitive strategic window for opportunities in the Global Tuberculosis Drugs Market?
  • 5. What are the technology trends and regulatory frameworks in the Global Tuberculosis Drugs Market?
  • 6. What is the market share of the leading vendors in the Global Tuberculosis Drugs Market?
  • 7. What modes and strategic moves are considered suitable for entering the Global Tuberculosis Drugs Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

  • 3.1. Introduction
  • 3.2. Market Outlook
  • 3.3. Drug Class Outlook
  • 3.4. Disease Type Outlook
  • 3.5. Geography Outlook
  • 3.6. Competitor Outlook

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Global plan against drug-resistant TB drives diagnosis and treatment enrollment
      • 5.1.1.2. HIV burden fuels LTBI case counts
      • 5.1.1.3. Rising prevalence of tuberculosis
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of MDR and XDR TB drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing research & development of new drug development
      • 5.1.3.2. Growing initiative from government organization for tuberculosis awareness
    • 5.1.4. Challenges
      • 5.1.4.1. Adverse side effects of tuberculosis drugs
  • 5.2. Cumulative Impact of COVID-19
  • 5.3. Porters Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry

6. Tuberculosis Drugs Market, by Disease Type

  • 6.1. Introduction
  • 6.2. Active TB
  • 6.3. Latent TB

7. Tuberculosis Drugs Market, by Drug Class

  • 7.1. Introduction
  • 7.2. Combination Drugs
  • 7.3. First-line Anti-TB Drugs
    • 7.3.1. Ethambutol
    • 7.3.2. Isoniazid
    • 7.3.3. Pyrazinamide
    • 7.3.4. Rifampin
  • 7.4. Second-line Anti-TB Drugs
    • 7.4.1. Capreomycin
    • 7.4.2. Ethionamide
    • 7.4.3. Levofloxacin
    • 7.4.4. Streptomycin

8. Americas Tuberculosis Drugs Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States
    • 8.6.1. California
    • 8.6.2. Florida
    • 8.6.3. Illinois
    • 8.6.4. New York
    • 8.6.5. Ohio
    • 8.6.6. Pennsylvania
    • 8.6.7. Texas

9. Asia-Pacific Tuberculosis Drugs Market

  • 9.1. Introduction
  • 9.2. China
  • 9.3. India
  • 9.4. Indonesia
  • 9.5. Japan
  • 9.6. Malaysia
  • 9.7. Philippines
  • 9.8. South Korea
  • 9.9. Thailand

10. Europe, Middle East & Africa Tuberculosis Drugs Market

  • 10.1. Introduction
  • 10.2. France
  • 10.3. Germany
  • 10.4. Italy
  • 10.5. Netherlands
  • 10.6. Qatar
  • 10.7. Russia
  • 10.8. Saudi Arabia
  • 10.9. South Africa
  • 10.10. Spain
  • 10.11. United Arab Emirates
  • 10.12. United Kingdom

11. Competitive Landscape

  • 11.1. FPNV Positioning Matrix
    • 11.1.1. Quadrants
    • 11.1.2. Business Strategy
    • 11.1.3. Product Satisfaction
  • 11.2. Market Ranking Analysis
  • 11.3. Market Share Analysis, By Quadrant
  • 11.4. Market Share Analysis, By Company
  • 11.5. Competitive Scenario
    • 11.5.1. Merger & Acquisition
    • 11.5.2. Agreement, Collaboration, & Partnership
    • 11.5.3. New Product Launch & Enhancement
    • 11.5.4. Investment & Funding
    • 11.5.5. Award, Recognition, & Expansion

12. Company Usability Profiles

  • 12.1. AstraZeneca
  • 12.2. Bayer AG
  • 12.3. Cipla Ltd.
  • 12.4. Lupin
  • 12.5. Merck & Co.
  • 12.6. Novartis AG
  • 12.7. Otsuka Novel Products
  • 12.8. Pfizer
  • 12.9. Sandoz International Gmbh
  • 12.10. Sanofi

13. Appendix

  • 13.1. Discussion Guide
  • 13.2. License & Pricing
  • 13.3. Contact Details
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.